Advertisement

Tumor Biology

, Volume 36, Issue 10, pp 8127–8136 | Cite as

Differential expression and alternative splicing of cell cycle genes in imatinib-treated K562 cells

  • Jing Liu
  • Jin Lin
  • Lin-Feng Huang
  • Bo Huang
  • Yan-Mei Xu
  • Jing Li
  • Yan Wang
  • Jing Zhang
  • Wei-Ming Yang
  • Qing-Hua Min
  • Xiao-Zhong Wang
Research Article

Abstract

Cancer progression often involves the disorder of the cell cycle, and a number of effective chemotherapeutic drugs have been shown to induce cell cycle arrest. The purpose of this study was to comprehensively investigate the effects of imatinib on the expression profile of cell cycle genes in the chronic myeloid leukemia (CML) K562 cell line. In addition, we also investigated alternative splicing of the cell cycle genes affected by imatinib, since an important relationship has been shown to exist between RNA splicing and cell cycle progression. Exon array analysis was performed using total RNA purified from normal and imatinib-treated K562 cells. We identified 185 differentially expressed genes and 277 alternative splicing events between the two cell groups. A detailed analysis by reverse transcription-PCR (RT-PCR) of key genes confirmed the experimental results of the exon array. These results suggested that treatment of K562 cells with imatinib shifts the expression and alternative splicing profiles of several cell cycle-related genes. Importantly, these findings may help improve imatinib treatment strategies in patients with CML and may be useful for imatinib resistance research and CML drug development.

Keywords

Imatinib K562 Chronic myeloid leukemia Cell cycle Gene expression profile Alternative splicing 

Notes

Acknowledgments

This study was supported by grants from the National Science Foundation of China (No. 81271912) and the Education Department of Jiangxi province, China (No. GJJ13041).

Conflicts of interest

None

Supplementary material

13277_2015_3493_MOESM1_ESM.xls (21 kb)
ESM 1 (XLS 21 kb)
13277_2015_3493_MOESM2_ESM.xls (42 kb)
ESM 2 (XLS 41 kb)
13277_2015_3493_MOESM3_ESM.xls (49 kb)
ESM 3 (XLS 49 kb)

References

  1. 1.
    Weinberg R, Lundberg A. Control of the cell cycle and apoptosis. Eur J Cancer. 1999;35(4):531–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36(3):131–49.CrossRefPubMedGoogle Scholar
  3. 3.
    Senese S, Lo Y, Huang D, Zangle T, Gholkar A, Robert L, et al. Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development. Cell Death Dis. 2014;5(10):e1462.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Alexander A, Keyomarsi K. Exploiting cell cycle pathways in cancer therapy: new (and old) targets and potential strategies. Nuclear Signaling Pathways and Targeting Transcription in Cancer. Springer; 2014; 337–72.Google Scholar
  5. 5.
    Nishimura N, Furukawa Y, Sutheesophon K, Nakamura M, Kishi K, Okuda K, et al. Suppression of ARG kinase activity by Sti571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/Ink4c. Oncogene. 2003;22(26):4074–82.CrossRefPubMedGoogle Scholar
  6. 6.
    Roussidis A, Mitropoulou T, Theocharis A, Kiamouris C, Papadopoulos S, Kletsas D, et al. Sti571 as a potent inhibitor of growth and invasiveness of human epithelial breast cancer cells. Anticancer Res. 2004;24(3A):1445–8.PubMedGoogle Scholar
  7. 7.
    Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer. 2005;92(10):1881–91.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Yin T, Wu Y-L, Sun H-P, Sun G-L, Du Y-Z, Wang K-K, et al. Combined effects of As4s4 and Imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004;104(13):4219–25.CrossRefPubMedGoogle Scholar
  9. 9.
    Liu J, Huang B, Xiao Y, Xiong H-M, Li J, Feng D-Q, et al. Aberrant expression of splicing factors in newly diagnosed acute myeloid leukemia. Onkologie. 2012;35(6):335–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Prinos P, Garneau D, Lucier J-F, Gendron D, Couture S, Boivin M, et al. Alternative splicing of SYK regulates mitosis and cell survival. Nat Struct Mol Biol. 2011;18(6):673–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Ahn E-Y, DeKelver RC, Lo M-C, Nguyen TA, Matsuura S, Boyapati A, et al. Son controls cell-cycle progression by coordinated regulation of RNA splicing. Mol Cell. 2011;42(2):185–98.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. David: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):3.CrossRefGoogle Scholar
  13. 13.
    Yin L-M, Jiang G-H, Wang Y, Wang Y, Liu Y-Y, Jin W-R, et al. Use of serial analysis of gene expression to reveal the specific regulation of gene expression profile in asthmatic rats treated by acupuncture. J Biomed Sci. 2009;16(1):46.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Jonuleit T, van der Kuip H, Miething C, Michels H, Hallek M, Duyster J, et al. BCR-ABL kinase down-regulates cyclin-dependent kinase inhibitor P27 in human and murine cell lines. Blood. 2000;96(5):1933–9.PubMedGoogle Scholar
  15. 15.
    Chang T-Y, Li Y-Y, Jen C-H, Yang T-P, Lin C-H, Hsu M-T, et al. Easyexon—a java-based Gui tool for processing and visualization of affymetrix exon array data. BMC Bioinformatics. 2008;9(1):432.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 1997;13(1):261–91.CrossRefPubMedGoogle Scholar
  17. 17.
    Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 1994;79(4):573–82.CrossRefPubMedGoogle Scholar
  18. 18.
    Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med. 2002;8(4):S32–S7.CrossRefPubMedGoogle Scholar
  19. 19.
    Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Investig Drugs. 2000;9(12):2903–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Du Y, Wang K, Fang H, Li J, Xiao D, Zheng P, et al. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by Imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood. 2006;107(4):1582–90.CrossRefPubMedGoogle Scholar
  21. 21.
    Majsterek I, Arabski M, Czechowska A, Pytel D, Morawiec Z, Morawiec-Bajda A, et al. Imatinib (Sti571) inhibits DNA repair in human leukemia oncogenic tyrosine kinase-expressing cells. Zeitschrift fur Naturforschung C. 2006;61(11/12):896.Google Scholar
  22. 22.
    Blasiak J, Gloc E, Pertynski T, Drzewoski J. DNA damage and repair in BCR/ABL-expressing cells after combined action of idarubicin, Sti571 and amifostine. Anti-Cancer Drugs. 2002;13(10):1055–60.CrossRefPubMedGoogle Scholar
  23. 23.
    Chang J-G, Yang D-M, Chang W-H, Chow L-P, Chan W-L, Lin H-H, et al. Small molecule amiloride modulates oncogenic Rna alternative splicing to devitalize human cancer cells. PLoS One. 2011;6(6):e18643.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Lundgren K, Allan S, Urushiyama S, Tani T, Ohshima Y, Frendewey D, et al. A connection between pre-mRNA splicing and the cell cycle in fission yeast: cdc28+ is allelic with prp8+ and encodes an RNA-dependent ATPase/helicase. Mol Biol Cell. 1996;7(7):1083–94.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Burns CG, Ohi R, Mehta S, O’Toole ET, Winey M, Clark TA, et al. Removal of a single Α-tubulin gene intron suppresses cell cycle arrest phenotypes of splicing factor mutations in saccharomyces cerevisiae. Mol Cell Biol. 2002;22(3):801–15.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Jing Liu
    • 1
  • Jin Lin
    • 1
  • Lin-Feng Huang
    • 1
  • Bo Huang
    • 1
  • Yan-Mei Xu
    • 1
  • Jing Li
    • 2
  • Yan Wang
    • 1
  • Jing Zhang
    • 1
  • Wei-Ming Yang
    • 1
  • Qing-Hua Min
    • 1
  • Xiao-Zhong Wang
    • 1
  1. 1.Department of Clinical LaboratoryThe Second Affiliated Hospital of Nanchang UniversityNanchangChina
  2. 2.Department of Clinical LaboratoryThe First Affiliated Hospital of Nanchang UniversityNanchangChina

Personalised recommendations